Hualan Biological Vaccine Inc.

SZSE:301207 Stock Report

Market Cap: CN¥10.0b

Hualan Biological Vaccine Management

Management criteria checks 3/4

Hualan Biological Vaccine's CEO is Wenjue An, appointed in Mar 2022, has a tenure of 2.83 years. directly owns 0.03% of the company’s shares, worth CN¥3.03M. The average tenure of the management team and the board of directors is 2.8 years and 4.6 years respectively.

Key information

Wenjue An

Chief executive officer

CN¥343.3k

Total compensation

CEO salary percentagen/a
CEO tenure2.8yrs
CEO ownership0.03%
Management average tenure2.8yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Oct 08
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk

Jul 25
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk

Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's

Jun 11
Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's

Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)

Apr 03
Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)

Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next

Apr 02
Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next

Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity

Apr 01
Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity

An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued

Mar 04
An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued

CEO

Wenjue An (35 yo)

2.8yrs

Tenure

CN¥343,300

Compensation

Ms. An Wenjue is GM & Director of Hualan Biological Vaccine Inc. (formerly known as Hualan Biological Bacterin Inc.) from April 28, 2022. She was Deputy General Manager of Hualan Biological Vaccine Inc. (f...

Leadership Team

NamePositionTenureCompensationOwnership
Wenjue An
GM & Director2.8yrsCN¥343.30k0.030%
CN¥ 3.0m
Ruowen Pan
Deputy GM & Director2.8yrsCN¥906.80k0.030%
CN¥ 3.0m
Chengyu Lv
CFO & Secretary4.6yrsno data0.0040%
CN¥ 403.3k

2.8yrs

Average Tenure

43yo

Average Age

Experienced Management: 301207's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wenjue An
GM & Director2.8yrsCN¥343.30k0.030%
CN¥ 3.0m
Ruowen Pan
Deputy GM & Director4.6yrsCN¥906.80k0.030%
CN¥ 3.0m
Kang An
Non-Independent Chairman4.6yrsno datano data
Bei Fan
Non-Independent Director4.6yrsno datano data
Xiaowei Ma
Non-Independent Director4.6yrsno data0.010%
CN¥ 1.0m
Wenqi An
Non-Independent Director4.6yrsno datano data
Dexin Li
Independent Director4.6yrsCN¥100.00kno data
Guanmu Dong
Independent Director4.6yrsCN¥100.00kno data
Yang Dong Sheng
Independent Director4.6yrsCN¥100.00kno data
Chaoyuan Ma
Non-Employee Supervisor4.6yrsno datano data
Yuancheng Lou
Supervisory Board Chairman4.6yrsno data0.00023%
CN¥ 23.0k

4.6yrs

Average Tenure

56yo

Average Age

Experienced Board: 301207's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 04:45
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hualan Biological Vaccine Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yizheng YangChina International Capital Corporation Limited
Kai WangCitic Securities Co., Ltd.
Mingrui WangEverbright Securities Co. Ltd.